
Absci Announces First Participants Dosed In Phase 1 Clinical Trial Of ABS-101, A Potential Best-In-Class Anti-TL1A ...
(MENAFN- GlobeNewsWire - Nasdaq) Absci becomes clinical stage company with ABS-101, first AI-designed biologic for IBD, beginning Phase 1 trial Preclinical data for ABS-101 demonstrates high potency and potential for quarterly dosing, an improvement in …